A Review Timeline Stretching Into Next Year
Mifepristone was first approved by the FDA in 2000. Over the years, the agency has repeatedly reaffirmed its safety and effectiveness while easing a number of restrictions, including dropping the requirement that it be dispensed in person. According to the latest filing, the review timeline is as follows:
- The safety study is expected to be completed by mid-December this year.
- A report on the findings will be released no later than March 2027.
- Only then will the FDA decide whether to impose new restrictions or other changes to the drug's use.
- The FDA is using a "statistical data mining method" on an electronic database that collects reports of side effects from major health networks and insurers.
- The agency is also considering several petitions proposing changes to how the drug is prescribed and distributed.
According to the FDA, this data analysis aims to uncover any previously unknown safety concerns with a drug that has been widely used for more than two decades.
Mixed Reactions
Since President Donald Trump returned to the White House, anti-abortion groups and their allies in Congress have repeatedly pressed the administration to revisit the drug in the hope of restricting its use. The FDA's extended timeline therefore disappointed them.















